资源描述：
《新型口服抗凝药达比加群》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。
1、新型口服抗凝药达比加群酯2015.8.13参考文献中华心血管病杂志编辑委员会血栓栓塞防治循证工作组.达比加群酯用于非瓣膜病心房颤动患者卒中预防的临床应用建议[J].中华心血管病杂志,2014,42(3):188-192.HoustonDS,ZarychanskiR.Dabigatranversuswarfarininpatientswithatrialfibrillation[J].NewEnglandJournalofMedicine,2009,361(8):1139-1151.MossJD,CifuAS.ManagementofAnticoagulationinPatie
2、ntsWithAtrialFibrillation.JAMA.2015Jul21;314(3):291-2.MartinaMookadam,FadiE.Shamoun,FaroukMookadam.NovelAnticoagulantsinAtrialFibrillation:APrimerforthePrimaryPhysician.JAmBoardFamMed.201528:510-522.Kang-LingWang,MD,GregoryY.H.Lip,MD,Shing-JongLin,MD,PhDandChern-EnChiang,MD,PhD,Non–VitaminK
3、AntagonistOralAnticoagulantsforStrokePreventioninAsianPatientsWithNonvalvularAtrialFibrillation,StrokeAHA,2015.July30GlundS,StangierJ,SchmohlM,etal,Safety,tolerability,andefficacyofidarucizumabforthereversaloftheanticoagulanteffectofdabigatraninhealthymalevolunteers,Lancet,2015Jun15.DOI:htt
4、p://dx.doi.org/10.1016/s0140-6736(15)60732-2
5、抗凝药物作用靶点“瀑布反应链条”MekajYH,MekajAY,DuciSB,MiftariEI.Neworalanticoagulants:theiradvantagesanddisadvantagescomparedwithvitaminKantagonistsinthepreventionandtreatmentofpatientswiththromboembolicevents.TherapeuticsandClinicalRiskManagement.2015;11:967-9
6、77.抗凝药物药代动力学MartinaMookadam,FadiE.Shamoun,FaroukMookadam.NovelAnticoagulantsinAtrialFibrillation:APrimerforthePrimaryPhysician.JAmBoardFamMed.201528:510-522.RE-LY试验:非劣效实验明确达比加群的疗效不劣于华法林中位随访2年1个危险因子的房颤患者不存在禁忌症达比加群酯110mgBID华法林1mg,3mg,5mg(INR2.0–3.0)达比加群酯150mgBIDHoustonDS,ZarychanskiR.Dabigat
7、ranversuswarfarininpatientswithatrialfibrillation[J].NewEnglandJournalofMedicine,2009,361(8):1139-1151.主要终点事件HoustonDS,ZarychanskiR.Dabigatranversuswarfarininpatientswithatrialfibrillation[J].NewEnglandJournalofMedicine,2009,361(8):1139-1151.出血风险HoustonDS,ZarychanskiR.Dabigatranversuswarfar
8、ininpatientswithatrialfibrillation[J].NewEnglandJournalofMedicine,2009,361(8):1139-1151.不良反应HoustonDS,ZarychanskiR.Dabigatranversuswarfarininpatientswithatrialfibrillation[J].NewEnglandJournalofMedicine,2009,361(8):1139-1151.AHA亚洲人群荟萃分析Kang-LingWang,MD,G
